Papp, K. A., Lebwohl, M. G., Puig Sanz, L., Ohtsuki, M., Beissert, S., Zeng, J., . . . Leonardi, C. L. (2021). Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Citación estilo ChicagoPapp, Kim A.|||0000-0001-9557-3642, et al. Long-term Efficacy and Safety of Risankizumab for the Treatment of Moderate-to-severe Plaque Psoriasis. 2021.
Cita MLAPapp, Kim A.|||0000-0001-9557-3642, et al. Long-term Efficacy and Safety of Risankizumab for the Treatment of Moderate-to-severe Plaque Psoriasis. 2021.
Precaución: Estas citas no son 100% exactas.